Abstract:Treatment of infections caused by staphylococci has become more difficult because of the emergence of multidrug-resistant strains as well as biofilm formation. In this study, we observed the ability of the phage lysin LysGH15 to eliminate staphylococcal planktonic cells and biofilms formed by Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Staphylococcus hominis. All these strains were sensitive to LysGH15, showing reductions in bacterial counts of approximately 4 log units within 30 min after treatment with 20 mu g/ml of LysGH15, and the MICs ranged from 8 mu g/ml to 32 mu g/ml. LysGH15 efficiently prevented biofilm formation by the four staphylococcal species at a dose of 50 mu g/ml. At a higher dose (100 mu g/ml), LysGH15 also showed notable disrupting activity against 24-h and 72-h biofilms formed by S. aureus and coagulase-negative species. In the in vivo experiments, a single intraperitoneal injection of LysGH15 (20 mu g/mouse) administered 1 h after the injection of S. epidermidis at double the minimum lethal dose was sufficient to protect the mice. The S. epidermidis cell counts were 4 log units lower in the blood and 3 log units lower in the organs of mice 24 h after treatment with LysGH15 than in the untreated control mice. LysGH15 reduced cytokine levels in the blood and improved pathological changes in the organs. The broad antistaphylococcal activity exerted by LysGH15 on planktonic cells and biofilms makes LysGH15 a valuable treatment option for biofilm-related or non-biofilmrelated staphylococcal infections. IMPORTANCE Most staphylococcal species are major causes of health care-and community-associated infections. In particular, Staphylococcus aureus is a common and dangerous pathogen, and Staphylococcus epidermidis is a ubiquitous skin commensal and opportunistic pathogen. Treatment of infections caused by staphylococci has become more difficult because of the emergence of multidrug-resistant strains as well as biofilm formation. In this study, we found that all tested S. aureus, S. epidermidis, Staphylococcus haemolyticus, and Staphylococcus hominis strains were sensitive to the phage lysin LysGH15 (MICs ranging from 8 to 32 mu g/ml). More importantly, LysGH15 not only prevented biofilm formation by these staphylococci but also disrupted 24-h and 72-h biofilms. Furthermore, the in vivo efficacy of LysGH15 was demonstrated in a mouse model of S. epidermidis bacteremia. Thus, LysGH15 exhibits therapeutic potential for treating biofilm-related or non-biofilm-related infections caused by diverse staphylococci.

LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice.

LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation

Lysgh15, A Novel Bacteriophage Lysin, Protects A Murine Bacteremia Model Efficiently Against Lethal Methicillin-Resistant Staphylococcus Aureus Infection

A Novel Bacteriophage Lysin, LysGH15, Protects a Murine Bacteremia 1 Model Efficiently against Lethal Methicillin-Resistant Staphylococcus 2 Infection

LysGH15 Effectively Control Murine Mastitis Caused by Staphylococcus Aureus

Antibacterial effects of phage lysin LysGH15 on planktonic cells and biofilms of diverse staphylococci.

An Ointment Consisting of the Phage Lysin LysGH15 and Apigenin for Decolonization of Methicillin-Resistant Staphylococcus Aureus from Skin Wounds

Recombinant Lysostaphin Protects Mice from Methicillin-ResistantStaphylococcus Aureuspneumonia

Α-Mangostin Suppresses NLRP3 Inflammasome Activation Via Promoting Autophagy in LPS-stimulated Murine Macrophages and Protects Against CLP-induced Sepsis in Mice

Combination Therapy of LysGH15 and Apigenin As a New Strategy for Treating Pneumonia Caused by Staphylococcus Aureus.

Use of the Antimicrobial Peptide Sublancin with Combined Antibacterial and Immunomodulatory Activities to Protect Against Methicillin-Resistant Staphylococcus Aureus Infection in Mice.

Phage Endolysin LysP108 Showed Promising Antibacterial Potential Against Methicillin-resistant Staphylococcus aureus

Enhancement of Macrophage Function by the Antimicrobial Peptide Sublancin Protects Mice from Methicillin-ResistantStaphylococcus Aureus

A Phage Lysin Fused to a Cell-Penetrating Peptide Kills Intracellular Methicillin-Resistant Staphylococcus Aureus in Keratinocytes and Has Potential As a Treatment for Skin Infections in Mice

Fosfomycin Protects Mice From Staphylococcus aureus Pneumonia Caused by α-Hemolysin in Extracellular Vesicles by Inhibiting MAPK-Regulated NLRP3 Inflammasomes.

The effect of immunoregulation of Streptococcus lactis L16 strain upon Staphylococcus aureus infection

Lung-Targeting Lysostaphin Microspheres for Methicillin-Resistant Staphylococcus Aureus Pneumonia Treatment and Prevention.

L-arginine attenuates Streptococcus uberis-induced inflammation by decreasing miR155 level

Methylsulfonylmethane protects against lethal dose MRSA-induced sepsis through promoting M2 macrophage polarization

Identification of a Novel Broad-Spectrum Endolysin, Ply0643, with High Antibacterial Activity in Mouse Models of Streptococcal Bacteriaemia and Mastitis

Single-Chain Fragment Variables Targeting Leukocidin ED Can Alleviate the Inflammation of Staphylococcus aureus-Induced Mastitis in Mice